Provid Pharmaceuticals Inc.

Provid has developed picomolar inhibitors of antigen binding to MHC II DRB1*15:01, the immune target associated with MS. PV-3212 promises high efficacy and superior safety. Provid is seeking a partner/investors to advance PV-3212 to the clinic.

Address

Monmouth Junction
New Jersey
United States
Visit website (opens in a new tab)
Loading